IL15 and atrial fibrillation: In an observational study of 90 patients receiving chimeric antigen receptor T-cell (CAR-T) therapy, the plasma levels of interleukin-6 (IL-6) and IL-15 in patients with new-onset fibrillation events during treatment were significantly higher than those in the group without AF, which may be associated with the development of AF (13).